Issues lobbied + lobbyists (6)
MMM — Medicare/Medicaid
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing; Alzheimers Screening and Prevention Act (ASAP) (HR 6130, S 3267); Concentrating on High-value Alzheimers Needs to Get to an End Act (CHANGE) (HR 4752. S 2379).
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TAX — Taxation/Internal Revenue Code
Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TRD — Trade (domestic/foreign)
Issues related to supply chain manufacturing and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
CPT — Copyright/Patent/Trademark
Issues related to pharmaceutical Intellectual Property (IP).
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
MAN — Manufacturing
Issues related to pharmaceutical manufacturing.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE